Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes

Pharmacological Research

Volumn 33, Issue 1, 1996, Pages 55-61

  Corsini, Alberto ^a   Arnaboldi, L ^a   Raiteri, M ^a   Quarato, P ^a   Faggiotto, A ^b   Paoletti, R ^a   Fumagalli, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Ricerca Bayer Farmacologia   (Italy)

Author keywords

BAY W 6228; Cerivastatin; Isoprenoids; Myocyte migration; Myocyte proliferation; Statins

Indexed keywords

CERIVASTATIN; CHOLESTEROL; FARNESOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID;

ANIMAL CELL; ARTERY MUSCLE; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; DOSE RESPONSE; FEMORAL ARTERY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

EID: 0029980255     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0009     Document Type: Article

References (38)

1. 1. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1991; 91 (Suppl 1B): IB3S-IBPS.
2. 2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
3. 3. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993; 69: S30-7.
4. 4. Wissler RW, Vesselinovitch D, Komatsu A. The contribution of studies of atherosclerosis lesions in young people to future research. Ann NY Acad Sci 1990; 598: 418-34.
5. 5. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-87.
6. 6. Katsuda S, Boyd HC, Fligner C, Ross R, Gown AM. Human Atherosclerosis. III. Immunocytochemical analysis of the cell composition of lesions of young adults. Am J Pathol 1992; 140: 907-14.
7. 7. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990; 10: 966-90.
8. 8. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on vascular lesions of the Council of Atherosclerosis, American Heart Association. Arterioscl Thromb 1994; 14: 840-56.
9. 9. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
10. 10. Habenicht AJR, Glomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980; 255: 5134-40.
11. 11. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117-25.
12. 12. Chen HW. Role of cholesterol metabolism in cell growth. Fedn Proc 1984; 43: 126-30.
13. 13. Brown MS, Goldstein JL. Multivalent feedback regulation of HMGCoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505-17.
14. 14. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990; 4: 3319-28.
15. 15. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA. The dual role of mevalonate in the cell cycle. J Biol Chem 1983; 258: 378-85.
16. 16. Glomset JA, Gelb MH, Farnsworth CC. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem Sci 1990; 15: 139-42.
17. 17. Corsini A, Raiteri M, Soma MR, Fumagalli R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991; 23: 173-80.
18. 18. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992; 95: 87-94.
19. 19. Corsini A, Raiteri M Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3 hydroxy-3methyl-glutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21A-8A.
20. 20. Angerbauer R, Rey P, Hubsch W, Phillips T, Schmidt D. BAY W 6228, a new generation HMG-CoA reductase inhibitor. I. Synthesis and structure activity relationship. X International Symposium on Drugs Affecting Lipid Metabolism 1992; Abstract Book: 69 (Abstract).
21. 21. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971; 50: 172-86.
22. 22. Skalli O, Ropraz P, Trezciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against alfa-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986; 103: 2787-96.
23. 23. Ross R. The pathogenesis of atherosclerosis - An update. New Engl J Med 1986; 314: 488-500.
24. 24. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 1978; 253: 1121-8.
25. 25. Corsini A, Bernini F, Cighetti G, Soma MR, Galli G, Fumagalli R. Lipophilic β-adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts. Biochem Pharmacol 1987; 36: 1901-6.
26. 26. Fisher RA, Yates F. Statistical Tables for Biological, Agricultural and Medical Research, 4th Edn, Oliver & Boyd, Edinburgh, 1953, p. 60.
27. 27. Corsini A, Verri D, Raiteri M, Quarato P, Paoletti R, Fumagalli R. Effect of 26-aminocholesterol, 27-hydroxycholesterol and 25-hydroxycholesterol on proliferation and cholesterol homeostatis in arterial myocytes. Arterioscl Thromb Vasc Biol 1995; 15: 420-8.
28. 28. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F. Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis 1990; 83: 9-14.
29. 29. Corsini A, Quarato P, Raiteri M, Paubert-Braquet M, Nguyen G, Piquot S, Bourgain RH, Fumagalli R, Paoletti R. Effect of nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res 1993; 27: 299-307.
30. 30. Smith LL, Johnson BH. Biological activity of oxysterols. Free Rad Biol Med 1989; 7: 285-332.
31. 31. Cox DC, Comai K, Goldstein AL. Effects of cholesterol and 25-hydroxycholesterol on smooth muscle cell and endothelial cell growth. Lipids 1988; 23: 85-8.
32. 32. Siperstein MD. Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 1984; 25: 1462-8.
33. 33. Scott W. Hydrophilicity and the differential pharmacology of pravastatin. In Wood, C, (ed); Lipid management: pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. London Round Table Series n. 16, Royal Society of Medicine Service. 1989, pp 17-25.
34. 34. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991; 88: 3628-32.
35. 35. Farnsworth CC, Gelb MH, Glomset JA. Identification of geranylgeranyl-modified proteins in HeLa cells. Science 1990; 247: 320-322.
36. 36. Casey PJ, Solsky PA, Der CJ, Buss JE. p21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989; 86: 8323-7.
37. 37. Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Ann Rev Cell Biol 1994; 10: 181-205.
38. 38. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989; 264: 20422-9.